Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genentech, Inc.
CytoVac A/S
Hoffmann-La Roche
Duke University
Duke University
Duke University
Duke University
Duke University
Radiation Therapy Oncology Group
Clinical Research Center for Solid Tumor, Korea
Duke University
Duke University
M.D. Anderson Cancer Center
Rigshospitalet, Denmark
Dartmouth-Hitchcock Medical Center
NYU Langone Health
Adnexus, A Bristol-Myers Squibb R&D Company